Assertio Therapeutics Inc

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Assertio Therapeutics Inc reports stellar Q4 performance and growth outlook

Assertio Therapeutics Inc (ASRT) delivered a robust Q4 performance with significant revenue and profit growth, despite facing challenges like supply issues.
The company's strategic focus on marketing, product development, and business expansion highlights a commitment to long-term success and shareholder value.
With a positive outlook for 2023 and a strong foundation in place, ASRT is poised for continued growth and value creation in the pharmaceutical market.

Assertio Therapeutics Inc (ASRT) reports robust Q1 results and raises 2023 guidance

Assertio Therapeutics Inc (ASRT) demonstrated solid financial performance in Q1 2023, with strong sales growth and improved profitability.
The company's strategic execution and upcoming acquisitions signal a positive outlook for future growth and expansion.
While facing integration challenges and market competition, Assertio's focus on product sales and operational efficiency bodes well for sustained success.

Assertio Therapeutics reports strong Q2 growth amidst generic competition

Assertio's Q2 performance showcased growth driven by key products and the acquisition of Spectrum Pharmaceuticals, positioning the company for future success.
While facing challenges from generic competition and operational expenses, Assertio remains focused on defending market share and creating shareholder value.
Management's confidence in overcoming short-term obstacles underscores a proactive approach to navigating market dynamics and driving growth.

Assertio Therapeutics Inc reports resilient Q3 performance amidst challenges

Assertio Therapeutics Inc navigated challenges in Q3 2023 with resilience, reporting positive financial metrics and improved liquidity.
New management changes and a focus on market access signal the company's commitment to driving growth and optimizing operations.
Despite lower sales for certain products, Assertio's strategic initiatives and financial performance position it well for future opportunities.
Analyst inquiries during the call highlighted areas for improvement and growth, indicating a proactive approach to addressing market dynamics.

Assertio Therapeutics reports robust Q4 results and outlines growth plans

Assertio Therapeutics Inc (ASRT) demonstrated strong financial performance in Q4 2023, driven by robust sales and positive EBITDA.
The company's strategic focus on Rolvedon's growth, profitability optimization, and future acquisitions positions it well for continued success.
While facing challenges from generic competition and operational issues, Assertio is poised to capitalize on growth opportunities and drive value creation.

Assertio Therapeutics Inc meets Q1 targets, eyes growth opportunities

Assertio Therapeutics Inc's Q1 2024 showcased strong sales performance, cost management, and cash generation. Despite challenges in generic competition and CEO transition, the company remains focused on growth opportunities.

Assertio Therapeutics reports solid Q2 results and projects growth

Assertio Therapeutics Inc (ASRT) demonstrated financial stability, growth potential, and resilience in the face of market challenges during Q2 2024.
The company's strategic focus on key products like Rolvedon and effective cost management strategies position it well for future success and profitability.
Maintaining guidance for 2024 and leveraging opportunities for growth underscore Assertio's commitment to delivering value to shareholders and stakeholders.

Assertio Therapeutics reports stable Q3 performance amid ROLVEDON transition

Assertio Therapeutics demonstrated stable financial performance and operational efficiency in Q3 2024, positioning the company for growth amidst challenges.
The company's focus on ROLVEDON and governance enhancements signal a strategic shift towards innovation and stakeholder value creation.
While facing challenges such as declining product sales and financial constraints, Assertio remains resilient and poised to capitalize on opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q3 2020 Results - Earnings Call Transcript

LAKE FOREST, Ill., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that the company will present at and participate in investor meetings at the Cantor Virtual Global Healthcare Conference. President, chief executive officer and director of Assertio, Todd Smith, will participate in the fireside chat with analyst Louise Chen on September 16, 2020 at 2:00 pm ET. The topics to be covered will be the status of the integration of Zyla Life Sciences, and the company’s business development strategy, financial results, current growth trends and milestones over the coming 12 months.

Assertio to Present at Cantor Virtual Global Healthcare Conference on September 16, 2020

Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q2 2020 Results - Earnings Call Transcript

Assertio (ASRT) delivered earnings and revenue surprises of -100.00% and -18.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Reports Q2 Loss, Misses Revenue Estimates

Shares of Assertio Holdings (NASDAQ:ASRT) moved higher by 0.9% in pre-market trading after the company reported Q2 results.

Recap: Assertio Holdings Q2 Earnings

Assertio Therapeutics (NASDAQ: ASRT) will be releasing its next round of earnings this Friday, August 07.

Preview: Assertio Therapeutics's Earnings

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for

LAKE FOREST, Ill., July  20, 2020  (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020 financial results will be released on Friday, August 7, 2020. Following the announcement, Assertio’s management team will host a live webcast at 8:30 a.m. Eastern Time to review the Company’s financials and operating results and provide a general business update. 

Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020

Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q1 2020 Results - Earnings Call Transcript

Assertio (ASRT) delivered earnings and revenue surprises of 225.00% and 85.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Beats Q1 Earnings and Revenue Estimates

Shares of Assertio Therapeutics (NASDAQ:ASRT) rose 9% in pre-market trading after the company reported Q1 results.

Recap: Assertio Therapeutics Q1 Earnings

-- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million --    -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt --

Assertio Therapeutics Announces First-Quarter 2020 Results

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Assertio (ASRT) Rating Upgrade to Buy

LAKE FOREST, Ill., April  08, 2020  (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced the completion and final results for its cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50% Senior Convertible Notes due 2021 (CUSIP: 249908AA2) (“2021 Notes”) and $34,522,000 of its 5.00% Senior Convertible Notes due 2024 (CUSIP: 04545LAA5) (“2024 Notes”, together with the 2021 Notes, the “Notes”). 

Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024

Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1

Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products

LAKE FOREST, Ill., March  11, 2020  (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50% Senior Convertible Notes due 2021 (CUSIP: 249908AA2) and $34,522,000 of its 5.00% Senior Convertible Notes due 2024 (CUSIP: 04545LAA5) (together, the “Notes”). The Offers are being made on the terms and subject to the conditions set forth in an Offer to Purchase dated March 11, 2020 (the “Offer to Purchase”) and are scheduled to expire at 11:59 p.m., New York City time, on April 7, 2020 unless extended by the Company (the “Expiration Time”). Holders of the Notes who have tendered (and not validly withdrawn) their Notes at or prior to the Expiration Time will be entitled to receive in cash $995 per $1,000 principal amount of Notes validly tendered (and not validly withdrawn), plus accrued and unpaid interest on such Notes up to, but not including, the date the Offers are settled which is expected to be promptly following the expiration of the Offers.

Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding  2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024

Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q4 2019 Results - Earnings Call Transcript

Assertio (ASRT) delivered earnings and revenue surprises of -200.00% and 17.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates

During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.

Assertio (ASRT) to Report Q4 Earnings: What's in Store?

Assertio Therapeutics: A Biotech Stock Trading Below Its Cash Balance

Also Announces its Senior Secured Debt Has Been Repaid in Full Also Announces its Senior Secured Debt Has Been Repaid in Full

Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million

Assertio (ASRT) closed at $1.35 in the latest trading session, marking a -0.74% move from the prior day.

Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know

Company Intends to Use Cash Proceeds to Retire its Outstanding Debt

Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million

Assertio (ASRT) closed the most recent trading day at $1.05, moving +0.48% from the previous trading session.

Assertio (ASRT) Gains But Lags Market: What You Should Know

Assertio (ASRT) closed the most recent trading day at $1.11, moving -0.89% from the previous trading session.

News for Assertio Therapeutics Inc Stock (ASRT)